Allergy Therapeutics Statistics

Total Valuation

AIM:AGY has a market cap or net worth of GBP 276.45 million. The enterprise value is 299.30 million.

Market Cap	276.45M
Enterprise Value	299.30M

Important Dates

The next estimated earnings date is Friday, June 27, 2025.

Earnings Date	Jun 27, 2025
Ex-Dividend Date	n/a

Share Statistics

AIM:AGY has 4.77 billion shares outstanding. The number of shares has increased by 180.43% in one year.

Current Share Class	n/a
Shares Outstanding	4.77B
Shares Change (YoY)	+180.43%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.19%
Owned by Institutions (%)	3.97%
Float	222.98M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.97
PB Ratio	-38.66
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-8.40
EV / Sales	5.38
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.32

Financial Position

The company has a current ratio of 1.60

Current Ratio	1.60
Quick Ratio	1.15
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-1.39
Interest Coverage	-8.01

Financial Efficiency

Return on equity (ROE) is -369.20% and return on invested capital (ROIC) is -48.41%.

Return on Equity (ROE)	-369.20%
Return on Assets (ROA)	-25.11%
Return on Invested Capital (ROIC)	-48.41%
Return on Capital Employed (ROCE)	-61.31%
Revenue Per Employee	90,943
Profits Per Employee	-58,252
Employee Count	612
Asset Turnover	0.78
Inventory Turnover	2.15

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +103.51% in the last 52 weeks. The beta is 1.23, so AIM:AGY's price volatility has been higher than the market average.

Beta (5Y)	1.23
52-Week Price Change	+103.51%
50-Day Moving Average	6.41
200-Day Moving Average	5.67
Relative Strength Index (RSI)	43.08
Average Volume (20 Days)	292,574

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AIM:AGY had revenue of GBP 55.66 million and -35.65 million in losses. Loss per share was -0.01.

Revenue	55.66M
Gross Profit	30.08M
Operating Income	-28.54M
Pretax Income	-35.61M
Net Income	-35.65M
EBITDA	-26.55M
EBIT	-28.54M
Loss Per Share	-0.01

Full Income Statement

Balance Sheet

The company has 21.68 million in cash and 44.52 million in debt, giving a net cash position of -22.84 million or -0.00 per share.

Cash & Cash Equivalents	21.68M
Total Debt	44.52M
Net Cash	-22.84M
Net Cash Per Share	-0.00
Equity (Book Value)	-7.15M
Book Value Per Share	-0.00
Working Capital	15.74M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -29.07 million and capital expenditures -3.06 million, giving a free cash flow of -32.13 million.

Operating Cash Flow	-29.07M
Capital Expenditures	-3.06M
Free Cash Flow	-32.13M
FCF Per Share	-0.01

Full Cash Flow Statement

Margins

Gross margin is 54.04%, with operating and profit margins of -51.27% and -64.05%.

Gross Margin	54.04%
Operating Margin	-51.27%
Pretax Margin	-63.98%
Profit Margin	-64.05%
EBITDA Margin	-47.69%
EBIT Margin	-51.27%
FCF Margin	n/a

Dividends & Yields

AIM:AGY does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-180.43%
Shareholder Yield	-180.43%
Earnings Yield	-12.90%
FCF Yield	-11.62%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AIM:AGY has an Altman Z-Score of -2.78. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.78
Piotroski F-Score	n/a